Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellat...
Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Because hepatic stellate cells (HSCs) play a major role in fibrosis, we focused on HSCs as a potential target for the treatment of liver fibrosis. In this study, we attempted to identify drug candidates to inactivate HSCs and found that several proteasome inhibitors (PIs) reduced HSC viability. Our data showed that a second-generation PI, carfilzom...
Alternative Titles
Full title
Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b3a0293e746b4e4aa4f6b1fa1200d07d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b3a0293e746b4e4aa4f6b1fa1200d07d
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-024-70296-8
